Xconomy | Boston - Business + Technology in the Exponential Economy

Biogen and Icahn Duel Again, Marinus Gets $20M, Vigilance Urged on Patent Reform, & More Boston-Area Life Sciences News
Cerulean Pharma Grabs $10M for Nanoparticle Drugs
Parasol Therapeutics Moves to Neighborhood with $3.25M in Seed Funding—Hunting for Universal Therapeutic to Battle Drug-Resistant Flu
Brightcove Forges Adobe Alliance, Investors Give in to DemandWare’s $15M Demands, Fate Therapeutics and Stemgent Team Up on Stem Cell Tech, & More Boston-Area Deals News
I-Therapeutix Raises $15M in Round Led by Polaris

Fetzer New CEO of Cerulean Pharma

Oliver Fetzer has been named the new CEO of Cerulean Pharma, a Cambridge, MA-based developer of nanoparticle-based drugs for cancer and other diseases, according to the company. Fetzer, who was previously senior vice president of corporate development and R&D at Lexington, MA-based Cubist Pharmaceuticals (NASDAQ:CBST), is taking over the chief executive post from veteran biotech executive and venture capitalist Alan Crane. Crane, who is the founding CEO of Cerulean and a venture partner at Polaris Venture Partners in Waltham, MA, has been named the biotech’s chairman of the board. Polaris is an investor in Cerulean.

Ryan McBride is Xconomy's correspondent. You can reach him at rmcbride@xconomy.com, or follow him on Twitter at http://twitter.com/Ryan_McBride.

Comments | Reprints | Share: